The diagnostic utility of folate receptor autoantibodies in blood by Sequeira, JM et al.
DOI 10.1515/cclm-2012-0577      Clin Chem Lab Med 2012; aop
 Review 
 Jeffrey M.  Sequeira ,  Vincent Th.  Ramaekers and  Edward V.  Quadros* 
 The diagnostic utility of folate receptor 
autoantibodies in blood 
 Abstract
 Folate supplementation reduces the risk of neural tube 
defect (NTD) pregnancy, and folinic acid has been used 
to correct cerebral folate deficiency (CFD) in children 
with developmental disorders. In the absence of systemic 
folate deficiency, the discovery of autoantibodies (AuAbs) 
to folate receptor  α (FR α ) that block the uptake of folate 
offers one mechanism to explain the response to folate 
in these disorders. The association of FR α AuAbs with 
pregnancy-related complications, CFD syndrome, and 
autism spectrum disorders and response to folate therapy 
is highly suggestive of the involvement of these AuAbs 
in the disruption of brain development and function  via 
folate pathways. The two types of antibodies identified in 
the serum of patients are blocking antibody and binding 
antibody. The two antibo dies can be measured by the spe-
cific assays described and exert their pathological effects 
either by functional blocking of folate transport as previ-
ously shown or hypothetically by disrupting the FR by an 
antigen-antibody-mediated inflammatory response. We 
have identified both IgG and IgM AuAbs in these condi-
tions. The predominant antibodies in women with NTD 
pregnancy belong to the IgG1 and IgG2 isotype and in CFD 
children, the IgG1 and IgG4 isotype. This review describes 
the methods used to measure these AuAbs, their binding 
characteristics, affinity, cross-reactivity, and potential 
mechanisms by which folate therapy could work. Because 
these AuAbs are associated with various pathologies dur-
ing fetal and neonatal development, early detection and 
intervention could prevent or reverse the consequences of 
exposure to these AuAbs. 
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 Introduction 
 Folate, in its various reduced forms, participates in numer-
ous single-carbon exchange reactions that are essential 
for purine/DNA/pyrimidine synthesis and amino acid 
metabolism [ 1 ]. The absorption of folate in the gut is pri-
marily mediated by a proton-coupled folate transporter 
in the upper ileum [ 2 ], and the cellular uptake of folate 
is mediated by folate receptor  α (FR α ) [ 3 ]. This receptor 
is highly expressed in reproductive tissues and plays the 
all-important role of providing folate to the embryo during 
the critical stages of development [ 4 ]. Folate deficiency in 
the mother can lead to pregnancy-related complications 
including neural tube defects (NTDs) in the fetus. Numer-
ous studies have now established the benefits of folate 
supplementation in reducing the incidence of NTD preg-
nancy [ 5 – 7 ]. The benefits of folate supplementation in the 
absence of systemic folate deficiency or genetic abnormali-
ties of folate pathways have not been adequately explained. 
The identification of FR autoantibodies (AuAbs) in women 
with a history of NTD pregnancy provides a mechanism by 
which the developing embryo could be deprived of folate 
[ 8 ]. Although the cause of this autoimmune disorder in 
mothers remains unknown, the AuAb directed against the 
FR α could disrupt folate transport to the fetus. This first 
report has been confirmed by two independent studies [ 9 , 
 10 ]. However, our own larger study in an Irish population 
failed to establish a statistically significant correlation of 
NTD pregnancy with the presence of FR α antibodies [ 11 ]. 
Nevertheless, the prevalence of the FR α AuAb and NTD 
pregnancy in Ireland remains higher than in the rest of 
Europe and the USA. These FR α AuAbs are also associ-
ated with numerous developmental disorders in children 
such as cerebral folate deficiency (CFD) syndrome [ 12 ], Rett 
syndrome [ 13 ], low functioning autism with neurological 
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deficits [ 14 ], and autism spectrum disorders (ASD) [ 15 , 
 16 ]. The AuAbs could exert their effect either by blocking 
folate transport or potentially by an antibody-mediated 
immune reaction. In the absence of gross fetal abnormali-
ties, exposure to these AuAbs during fetal development or 
in early infancy could disrupt the structural refinement of 
the brain and cause functional deficits in later life. These 
observations further attest to the importance of folate 
status during early brain development and to the identi-
fication of factors that could disrupt this essential need. 
Early detection and prompt treatment to correct the defi-
cits could prevent or reverse the neurodevelopmental dis-
orders due to FR α autoimmunity and folate deficiency. 
 Discovery of FR α AuAbs 
 Folate deficiency in humans leads to hyperhomocysteine-
mia and megaloblastic anemia [ 1 ]. The rapid onset of the 
deficiency and the severity of the hematological abnor-
mality present clinically as anemia and the condition is 
promptly diagnosed and treated. In adults, neurological 
deficits such as that seen in B12 deficiency are normally 
not associated with acquired folate deficiency other than 
some reports of neurological deficits and dementia in the 
elderly population [ 17 ,  18 ]. Maternal folate deficiency has 
been associated with pregnancy-related complications 
including miscarriages and birth defects [ 19 ]. Chemothera-
peutic drugs that interfere with folate metabolism [ 20 ] 
and many autoimmune disorders [ 21 ] are also implicated 
in pregnancy-related complications. Reports of the effects 
of folate deficiency on embryonic development and func-
tional deficits have been gathered primarily from animal 
models of dietary folate deficiency [ 22 ,  23 ] and, more 
recently, from mouse gene knockout models [ 24 ,  25 ]. Anti-
bodies to various tissue proteins can be teratogenic to the 
developing embryo, as amply demonstrated in rat models 
[ 26 ]. We hypothesized that perhaps an autoimmune mech-
anism involving the primary transporter of folate to the 
fetus could play a role in fetal brain abnormalities, and 
therefore, a systematic analysis of FR α expression and the 
effects of an antibody to this protein was investigated in a 
rat model [ 4 ]. Immunohistochemical localization of FR α in 
the rat with a polyclonal rabbit antiserum to rat placental 
FR α demonstrated high expression in reproductive tissues 
and in the developing embryo. Subsequent studies with 
pregnant dams showed that the antiserum induced embry-
onic resorptions at higher doses and malformations or no 
gross structural defects at lower doses when administered 
on gestation day 8 [ 4 ]. These effects were preventable with 
the use of pharmacologic doses of folinic acid, suggesting 
that the antibodies may be blocking the folate uptake  via 
the FR α , leading to folate deficiency in the embryo and 
to the ensuing pathology. The rescue with folinic acid, 
which is transported  via the reduced folate carrier (RFC), 
suggested that the deleterious effects of the antibodies 
could be prevented by treating with adequate amounts 
of folinic acid. This suggested that if the AuAbs to the FR 
in women with NTD pregnancy are contributing to the 
fetal abnormalities, these could be rescued by folinic acid 
treatment. Subsequent analysis of human serum samples 
demonstrated the presence of FR α AuAbs in women with 
a history of an NTD pregnancy [ 8 ]. The properties of these 
antibodies were confirmed by the high-affinity binding to 
FR α ( K a = 10 9 – 10 10 L/mol) and by their ability to block folate 
uptake in FR α -expressing KB cells in culture [ 8 ]. 
 The observation of severely reduced cerebral spinal 
fluid (CSF) folate levels in children with the CFD syndrome 
prompted the analysis of serum from these children for the 
presence of FR α AuAbs, which were found in 89% of the 
patients with this disorder. Intervention with pharmaco-
logic doses of folinic acid normalized the CSF folate levels 
with clinical improvement [ 12 ]. Because a number of the 
patients with CFD showed symptoms that were similar to 
those associated with ASD, we evaluated patients with low 
functioning autism and identified FR α -blocking antibod-
ies in 76% of these patients [ 14 ]. This analysis was subse-
quently extended to children with ASD. In the American 
ASD population, more than 75% of the children had FR 
AuAbs, and there was a significant correlation between 
those with blocking AuAbs and those with lower CSF 
folate concentrations [ 15 ]. Treatment with folinic acid over 
4 months showed a significant improvement in verbal 
communication, receptive and expressive language, atten-
tion, and stereotypical behavior. An independent study 
conducted in Belgium provided similar results for the FR α -
blocking antibody and, in addition, showed that parental 
FR α AuAbs were associated with an increased risk for ASD 
[ 16 ]. This review provides data on the detailed characteri-
zation of FR α AuAbs and methods for the measurement of 
these antibodies in serum to diagnose FR α autoimmune 
disorders along with a discussion of published reports. 
 Methods 
 Identification of AuAb isotypes 
 Apo-FR α (FR α without bound folate), purified from 
human milk using a protocol previously described for 
human placental FR [ 8 ,  12 ], was covalently attached in 
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96-well maleic anhydride-coated plates (Pierce™). Unre-
acted sites were blocked with goat serum, and an aliquot of 
test serum or plasma was added and incubated overnight 
at 4 ° C. The presence of bound human AuAbs was detected 
by complexing with a secondary peroxidase-conjugated 
goat antibody against human IgG or human IgM (Vector 
Laboratories™), followed by a colorimetric reaction with 
tetramethylbenzidine. The determination of the IgG iso-
types was performed in a similar assay using biotin-con-
jugated secondary monoclonal antibodies against human 
IgG1, IgG2, IgG3, or IgG4 (Sigma™). After incubation with 
an avidin-peroxidase complex (Vector Laboratories™), a 
colorimetric reaction with tetramethylbenzidine identi-
fied an AuAb isotype bound to the FR α . 
 Immunological cross-reactivity of FR α 
antigen derived from animal sources 
 FR α from human, bovine, goat, and camel milk was 
used as the antigen to measure the immunoreactivity of 
FR antigen with the human AuAb in a functional block-
ing assay whereby the binding of Ab to FR α prevents the 
subsequent binding of [ 3 H] folic acid to FR α . In this assay, 
0.3 pmol of each FR α antigen was incubated with acid/
charcoal-treated serum ( vide infra ) that was titrated to 
block approximately 0.1 pmol of human milk FR α (used 
as reference). After overnight incubation at 4 ° C, [ 3 H] folic 
acid was added for 20 min at 25 ° C. Unbound folic acid was 
adsorbed to dextran-coated charcoal ( vide infra ), and the 
amount of bound [ 3 H] folic acid FR α in the supernatant 
was determined. The decrease in bound [ 3 H] folic acid rep-
resents the amount of FR α blocked by the AuAb. 
 Immunoreactivity of AuAb with native 
and denatured FR α 
 Purified human milk FR α was denatured using urea and 
DTT, with a temperature of 50 ° C, followed by alkylation 
with  n -ethylmaleimide to prevent refolding. Urea and 
DTT were removed by dialysis, and the denaturation of 
FR α was confirmed by a complete loss of [ 3 H] folic acid 
binding to the protein. The denatured FR α was then 
tested for immunoreactivity against the native receptor in 
the blocking FR α AuAb assay ( vide infra ). Immunological 
cross-reactivity was also tested in an ELISA-based assay 
for binding AuAbs. Acid/charcoal-treated serum samples 
( vide infra ) to remove endogenous folate were incubated 
with 100-fold excess native FR α or with FR α denatured 
overnight at 4 ° C and added to maleic anhydride-coated 
ELISA plates containing covalently bound native FR α . 
The same serum samples without preincubation with 
excess native, or denatured FR α were used as positive 
controls, and AuAb-negative serum samples were used to 
correct for any non-specific reactivity in the assay. 
 Determination of optimum binding 
of AuAb to FR α and affinity constant 
 Acid/charcoal-treated serum from subjects positive for 
blocking AuAb were incubated with 0.3 pmol of purified 
apo-FR α from human milk. At various periods (1 – 24 h), 
an aliquot was removed and tested for the quantity of the 
remaining apo-FR α by incubating it with [ 3 H] folic acid for 
20 min followed by the measurement of bound [ 3 H] folic 
acid. The decrease in apo-FR α fraction compared with the 
FR α sample lacking AuAb indicated the inhibition of [ 3 H] 
folic acid binding by the blocking AuAb. 
 For the determination of the affinity of the AuAb, 
increasing amounts of apo-FR α purified from human 
milk were incubated overnight at 4 ° C with a constant 
amount of serum containing AuAbs. [ 3 H] Folic acid was 
added, and the bound folate was subtracted from the 
total folate binding capacity of the receptor to determine 
the quantity of receptors blocked (in picomoles) by the 
antibody. The ratio of the blocked receptor to the free 
apo-receptor (B/F) was used for the Scatchard analysis 
of the binding data. 
 Displacement of bound AuAbs from FR by folate 
 To determine the form and concentration of folate needed 
to displace the bound AuAb from FR α , varying concentra-
tions of folic acid or 5-methyl folate (20 – 800 nM) were 
used to determine the concentration required to dis-
place the FR α -bound AuAb. Acid/charcoal-treated serum 
samples containing blocking IgG AuAb were added to a 
maleic anhydride ELISA plate with covalently attached 
FR α . After overnight incubation at 4 ° C, various concen-
trations of either folic acid or 5-methyl folate were added 
to the wells, and the reference (control) wells contained 
no added folate. After incubation for 2 h at 25 ° C, the wells 
were washed, and the quantity of the blocking IgG AuAb 
remaining bound to the FR α in each well was determined 
by incubating with a second peroxidase-conjugated anti-
human IgG antibody for 1 h at 25 ° C and a colorimetric 
reaction with tetramethylbenzidine. Any reduction in IgG 
bound, compared with the reference wells lacking added 
folate, represented the displacement of bound AuAb by 
the specific folate form used. 
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 Current methodology of binding 
and blocking AuAb assays 
 Although the initial identification of the FR α AuAbs was 
done by isolating IgG in the patient ’ s serum that bound 
[ 3 H] folic acid-labeled FR α , technical refinements were 
deemed necessary to analyze larger number of samples, 
and therefore, a functional blocking assay was developed 
that specifically identifies antibodies that, by virtue of 
their binding location, prevent the binding of folate and 
therefore prevent the transport of folate  via the FR α . A 
second assay developed for the detection of binding anti-
bodies utilized an ELISA format whereby apo-FR α immo-
bilized in an ELISA plate assay would capture any IgG 
that would bind to the protein and could be quantitatively 
identified using a peroxidase enzyme-linked second anti-
body and a colorimetric substrate. 
 Assay for blocking AuAbs to FR α 
 The testing for blocking AuAbs against FR α was per-
formed by measuring the blocking of radiolabeled folic 
acid binding to a known amount of purified FR α from 
human milk as previously described [ 8 ]. Briefly, 200  μ L of 
serum was acidified with 300  μ L of 0.1 M glycine/HCl, pH 
2.5/0.5% Triton X-100/10 mM EDTA and was added to 12.5 
mg of dextran-coated charcoal pellet to remove the free 
folate in the sample. After centrifugation, the supernatant 
was collected and the pH was neutralized with 40  μ L of 
1 M dibasic sodium phosphate. This sample was incubated 
overnight at 4 ° C with 0.34 pmol of apo-FR α purified from 
human milk. [ 3 H] Folic acid was added, and the mixture 
was incubated for 20 min at room temperature. Free [ 3 H] 
folic acid is then adsorbed to dextran-coated charcoal 
(5% activated charcoal, 1% dextran in 0.1 M sodium phos-
phate buffer, pH 7.4), and the receptor-bound radioactiv-
ity in the supernatant fraction was determined. Blocking 
AuAbs prevent the binding of [ 3 H] folic acid to FR α , and 
the AuAb titer is expressed as picomoles of FR α blocked 
per milliliter of serum. The blocking Ab could be either 
IgG or IgM, and this method does not identify any specific 
antibody type. 
 Assay for binding AuAbs to FR α 
 An ELISA-based measurement was used to determine the 
presence of IgG immunoglobulins that bind to epitopes 
on purified apo-FR α . In this assay, apo-FR α purified 
from human milk was immobilized in 96-well maleic 
anhydride plates (Pierce). Unreacted sites were blocked 
with goat serum. Aliquots of plasma or serum were added 
and incubated overnight at 4 ° C. The presence of AuAbs 
was detected by complexing with a second peroxidase-
conjugated goat antibody against human IgG, followed 
by a colorimetric reaction with tetramethylbenzidine. The 
AuAb titer (IgG) was quantified from a standard curve 
using known amounts of human IgG captured in a protein 
A-coated ELISA plate and color development as described 
above. Non-specific binding was determined using nega-
tive control serum samples. Data are presented as  ‘ binding 
AuAbs ’ and expressed as picomoles of FR α binding IgG 
per milliliter of serum. 
 Results and discussion 
 Properties of FR α AuAbs 
 Stability of AuAbs upon storage 
 The first study identifying FR α AuAbs was done with 
fresh serum samples [ 8 ]. However, subsequent studies 
in both NTD pregnancy and CFD syndromes were done 
with serum samples kept frozen for various periods. 
Because the stability of proteins in a biological sample is 
a valid concern, we performed both blocking and binding 
assays on samples stored under two different conditions. 
Serum samples containing varying titers of AuAbs to 
FR α were aliquoted and stored at either 4 ° C or  − 20 ° C. At 
various time intervals (1, 85, 155, 266, 337, and 407 days), 
an aliquot was assayed for blocking and binding AuAb 
to FR α ( Figure 1 ). About half the samples stored at 4 ° C 
showed some decrease in blocking Ab titer over time. 
However, the decrease amounted to  < 45% of the initial 
mean value after more that 10 months. This decrease was 
much less for samples stored at  − 20 ° C, in that only 30% 
of the samples showed a decrease in blocking, with the 
decrease amounting to  < 25% of the initial mean value. 
A similar analysis of binding Ab showed a decrease 
in titer in 42% of the samples, with the mean decrease 
amounting to 33% of the initial value in samples stored 
at 4 ° C. As with the blocking Ab, the binding Ab was more 
stable when stored at  − 20 ° C, with only 8% of the samples 
showing any decrease in titer. This decrease amounted to 
24% of the initial mean value. In no case did the Ab titer 
change from positive to negative. From these data, it was 
clear that the FR α antibody in serum was relatively stable 
under long-term storage conditions and could be used for 
future studies. 
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 Specific AuAb types in FR autoimmune disorders 
 The initial trigger for FR α AuAb production in these disor-
ders is not known, and therefore, to better understand the 
immune response, the specific type of immunoglobulin 
produced was identified using isotype-specific monoclo-
nal antibodies. As shown in  Table 1 , all subjects with this 
autoimmune condition had IgG antibodies, with IgG1 as the 
predominant isotype. Mothers with NTD pregnancy (40%) 
and ASD subjects (14%) also contained IgG2; CFD (21%) 
and ASD (7%) subjects also had IgG3 isotype. Although 
the occurrence of IgG4 is rare, 79% of the CFD subjects 
and 14% of the ASD subjects had this isotype. The conver-
sion to IgG4 is believed to occur as a result of repeated and 
frequent exposure to an antigen. A number of patients 
(26% – 28%) also had IgM antibodies with blocking activ-
ity, and it is likely to be the only antibody type in patients 
who are negative for binding Ab because binding Ab assay 
only detects IgG. In CFD subjects, one factor contributing 
to the increase in antibody titer is the daily consumption 
of animal milk, which contains substantial amounts of 
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 Figure 1   Effect of storage condition on stability of AuAb titer in serum. 
 Samples were assayed for binding (n = 11) and blocking (n = 20) antibody at various times following storage at 4 ° C or  − 20 ° C, which showed 





 Percent IgG isotypes  IgM 
 
 IgG1  IgG2  IgG3  IgG4 
 NTD (n = 7)  100  100  40  0  0  28 
 CFD (n = 19)  100  68  0  21  79  5 
 ASD (n = 78)  74  100  14  7  14  26 
 Table 1   Identification of antibody type and IgG isotype in subjects 
positive for the folate receptor autoantibody. 
 NTD, mothers with a history of neural tube defect pregnancy; CFD, 
children with cerebral folate deficiency syndrome; ASD, children 
with autism spectrum disorder. 
and a compromised immune barrier in the gut either due 
to infection and/or inflammation appears to present the 
antigen to the immune system to mount a response. The 
substantial similarity in the primary structure of FR α 
from animal origin with that of human FR α provides the 
epitopes for molecular mimicry to produce antibodies that 
cross-react. This is evident from the cross-reactivity of FR 
AuAbs with milk-derived FR α of animal origin ( Figure 
2 B). This hypothesis is further supported by the dramatic 
decrease in antibody titer in CFD patients maintained on a 
dairy-free diet [ 27 ]. However, patients with ASD who have 
been kept off milk for various reasons still show antibody 
titers that are considered elevated. Non-compliance to a 
strict dairy-free diet may partially contribute to the persis-
tent Ab titer in ASD. Camel milk has been touted as ben-
eficial in ASD. Unfortunately, the FR α from camel milk is 
highly reactive with the AuAb ( Figure 2 B) and is likely to 
increase the antibody titer, as we have observed in cases 
when camel milk was introduced (unpublished data). 
 Binding characteristics of the AuAbs 
 In developing assays for the detection of blocking and 
binding antibodies, the time of incubation for optimum 
binding has to be considered. As shown in  Figure 3 A, 
optimum binding required overnight incubation at 4 ° C, 
and the long incubation time required may be a function 
of the antibody and antigen concentration in the incu-
bation reaction. However, the binding is a high-affinity 
interaction in the nanomolar range, as shown in  Figure 
3 B. This is consistent with the affinity constants of 10 9 – 10 10 
L/mol that we have previously reported [ 8 ,  12 ]. 
 Another property of the antibodies relevant to the assay 
development was the inability of the antibodies to react with 
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denatured and linearized polypeptide of FR in the ELISA 
assay, which supports the notion that the AuAbs are con-
formation specific and can bind to the native protein with or 
without the folate attached ( Figure 4 A). Similarly, the dena-
tured FR α protein does not react in the blocking assay, indi-
cating the need for a fully functional native protein in this 
assay as well ( Figure 4 B). Therefore, synthetic peptides or 
truncated protein fragments are unlikely to be suitable anti-
gens in future assay developments for FR α AuAbs. 
 In addition to decreasing the antibody titer, the treat-
ment of choice in these autoimmune disorders has been 
to administer daily pharmacologic doses of folinic acid or 
methylfolate orally to restore the CSF folate and correct 
the CFD. These two reduced forms of folates can be trans-
ported by alternate routes such as the high-capacity/
low-affinity RFC, which can transport these folates when 
the local concentration is increased. An empirical dose 
of 0.5 – 2 mg of folinic acid or 0.1 – 0.25 mg of methylfolate 
per kilogram of body weight for the two reduced form of 
folates has been reached by trial and error. The advantage 
of administering 5-methylfolate is that, in addition to 
being transported  via the RFC, a high local concentration 
of methylfolate, which also binds to the FR α with rela-
tively high affinity, could effectively dissociate the AuAb 
from the FR α and prevent AuAb from binding to the FR α 
while it is transporting the methylfolate  via this recep-
tor. However, this form of folate has to be processed  via 
the methionine synthase pathway for folate-dependent 
reactions. The advantage of using folinic acid is that it 
is an approved drug tested for use at high doses in other 
conditions and is readily available for folate-dependent 
reactions. Because a fraction of the folinic acid can be 
converted to methylfolate during absorption in the gut, it 
can increase the local concentration of folinic acid as well 
as methylfolate. The ability of methylfolate to displace 
the bound antibody from FR α , tested using Ab-positive 
serums, showed that 50 nM 5-methylfolate was able to dis-
place more than 80% of the bound Ab ( Figure 5 A). Under 
identical conditions, folic acid was not as effective and 
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 Figure 3   Time course of blocking AuAb binding to FR α from human milk and binding affinity. 
 Square symbols represent data with AuAb from a CFD subject, and the circles represent data with AuAb from a mother with a history of an 
NTD pregnancy. Optimum complex formation required overnight incubation (A). However, a Scatchard analysis of the binding data indicated 
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 Figure 2   FR α concentration in milk from different species and cross-reactivity of blocking FR AuAb from human serum with these antigens: 
(A) concentration of FR α from different species and (B) immunological cross-reactivity of FR α AuAb against each of the FR α antigens. 
 The data are plotted as cross-reactivity of antigens relative to human FR α . The AuAb shows higher cross-reactivity with bovine and camel 
milk FR α , which are sources of milk for human consumption. 
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a high affinity for FR α ( Figure 5 B). As previously reported 
[ 3 ], folinic acid binds weakly to FR α and therefore cannot 
displace the antibody. Based on the  K t of approximately 
5 nM for transport of methylfolate  via the FR α [ 28 ] and a 
concentration of 50 nM required to displace the AuAb, an 
oral dose sufficient to increase the folate concentration in 
the circulation to 50 – 100 nM would be sufficient to nor-
malize the CSF folate status. Because of the  K t of approxi-
mately 5  μ M for folinic acid transport  via the RFC [ 29 ], the 
folinic acid dose would have to be considerably higher to 
increase the concentration of this folate to the 10- to 50- μ M 
range. The conversion of a fraction of this during intesti-
nal absorption would also provide some methylfolate to 
displace the AuAb and be transported  via the FR α . 
 Using the current assays described in the Methods 
section, we have analyzed serum samples from disor-
ders linked to pregnancy and fetal abnormalities to 
neurodevelopmental disorders in children, and the results 
are summarized in  Table 2 . 
 The significant association of FR α AuAbs with NTD 
pregnancy has been confirmed by three independent 
studies [ 8 – 10 ]. The lack of a significant association of FR α 
antibodies with NTD pregnancy in the Irish population 
[ 11 ], despite the higher prevalence of the antibody and 
the higher incidence of NTD pregnancy than in the US 
population, points to other compounding factors. What 
additional genetic and epigenetic factors contribute to 
the NTD outcome in different populations? Whether FR α 
AuAbs contribute to the pathology in the Irish popula-
tion is yet to be determined. However, the association of 
FR α AuAbs with neurodevelopmental disorders including 
CFD syndromes and ASD is very strong, and treatments 
to reduce the antibody titer and inflammation along with 


















































 Figure 4   Binding of AuAb to native and denatured FR α . 
 The lack of neutralization of the antigen-antibody complex formation by denatured FR α and the effective neutralization by native FR α 










































0 025 50 75 100 200 200400 400 600 800800




 Figure 5   Displacement of blocking AuAb from FR α by 5-methyl folate (A) and folic acid (B). 
 A preformed FR-AuAb complex was incubated with increasing amounts of folate to determine the lowest concentration of folate needed to 
displace most of the AuAb. Square symbols represent data obtained with AuAb from CFD subjects, and the circles represent data obtained 
with AuAb from mothers with a history of an NTD pregnancy. 
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cerebral folate levels have been extremely beneficial in 
correcting and preventing neurological deficits. 
 As we age, the immune system also changes, leading to 
immunosenescence, and therefore, AuAbs to many antigens 
are prevalent in the elderly population [ 30 ,  31 ]. This trend 
is also seen for blocking FR α AuAbs, whose prevalence 
increases from  < 2% in those younger-than-16-years age 
group to approximately 10% in the 18-to-35-years age group, 
and with approximately 25% of the older-than-65-years 
age group testing positive for the antibody ( Figure 6 ). The 
significance of the increase in antibody titer in the elderly 
population, and if this contributes to CFD and dementia 
or decrease in brain function and if this population would 
benefit from folate supplementation, needs to be evaluated. 
 Utility of FR AuAb testing 
 The identification of FR AuAbs and its  association with 
pregnancy-related  complications  as  well  as  neuro-
 Condition 
 
  Percent prevalence  Reference 
  Blocking AuAb 
 
 Binding AuAb 
 
 Control 
 Blocking  Binding 
 NTD (n = 12)  –  75  –  10  8 
 NTD (n = 103)  17  30  13  33  11 
 CFD (n = 28)  89  –  0  –  12 
 RS (n = 33)  24  –  –  –  13 
 LFA (n = 25)  76  –  0  –  14 
 ASD (n = 93)  60  44  –  –  15 
 ASD (n = 75)  46  –  3  –  16 
 Table 2   Prevalence of FR AuAbs in various conditions .
 NTD, mothers with a history of neural tube defect pregnancy; CFD, children with cerebral folate deficiency syndrome; LFA, children with 





















 Figure 6   Prevalence of AuAb to FR α with aging. 
 Serum samples from subjects of different age groups with no known 
disease condition were analyzed for the presence of blocking AuAb 
to FR α . 
developmental disorders adds a whole new dimension to 
evaluating and treating folate deficiency-related disorders. 
It highlights the role of folate in embryonic and neural 
development. The association of FR α AuAbs in a majority 
of ASD children and one or both parents and significant 
improvement in the core clinical symptoms of ASD with 
folinic acid therapy further highlights the role of folate in 
structural and functional integration of the developing 
brain. Even though we do not understand the molecular 
basis for the FR autoimmune disorder, identifying women 
and children at risk could be accomplished by a simple 
blood test. Considering the risk to fetal as well as neona-
tal brain development, early detection and intervention is 
likely to yield the best outcome. Population studies involv-
ing children, women, and men of all ages should be ini-
tiated to evaluate the prevalence, association, and risk of 
FR α AuAbs. 
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